This analysis of data from the CATT and IVAN trials found no evidence that VEGFR2 genotypes affect response to anti-VEGF therapy in patients with wet AMD, contrary to a previous report.
Powered by Steuernachrichten
AAO News Archive
- Deal struck to develop integrin antagonist treatment
- New low-add multifocal IOLs yield higher patient satisfaction
- Regeneron, Bayer to develop AMD combination therapy
- FDA approves wide-field imaging system for newborns
- Brain mapping may someday lead to vision-restoring therapies
- FDA warns of loose safety seals on eye drops
- Stem cells regrow human lens, corneal tissue
Genes don’t affect response to anti-VEGF treatment
- Details